Ramses Forsyth

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years

Research Subjects

Research Interests

Ramses Forsyth has a total of 342 co-authors. Here are the top co-authors by number of shared publications:

Guillaume E. Courtoy
Laboratory of Experimental Pathology (EXPA), Vrije Universiteit Brussel, Brussels, Belgium
18 shared publications
Wim Waelput
Laboratory of Experimental Pathology (EXPA), Vrije Universiteit Brussel, Brussels, Belgium
18 shared publications
Aleksandar Murgaski
King’s College London 3 Centre for Inflammation Biology and Cancer Immunology, Cancer Research UK City of London Centre, School of Immunology and Microbial Sciences London, United Kingdom
17 shared publications
Ayla Debraekeleer
Lab of Cellular and Molecular Immunology, Brussels Center for Immunology, Vrije Universiteit Brussel, Brussels, Belgium
17 shared publications
Bruno Dombrecht
13VIB Discovery Sciences, VIB, Ghent, Belgium
17 shared publications
Catelijne Stortelers
13VIB Discovery Sciences, VIB, Ghent, Belgium
17 shared publications

Latest Publications

Sort by

Open Access
Website
Google Scholar
- 10 August 2026
- Published by Springer Nature in Breast Cancer Research
Micro-CT radiomics reveals the microcalcification-surrounding tissue interface as the diagnostic epicenter of breast microcalcifications
by Redona Brahimetaj, Jan Cornelis, Guillaume Courtoy, Wim Waelput, Inneke Willekens, Johan De Mey, Ramses Forsyth, Bart Jansen
Website
Google Scholar
- 10 August 2026
- Published by Springer Nature in Breast Cancer Research
Open Access
Micro-CT radiomics reveals the microcalcification-surrounding tissue interface as the diagnostic epicenter of breast microcalcifications
by Redona Brahimetaj, Jan Cornelis, Guillaume Courtoy, Wim Waelput, Inneke Willekens, Johan De Mey, Ramses Forsyth, Bart Jansen
Open Access
Website
Google Scholar
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S9 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
by Sana M. Arnouk, Daliya Kancheva, Helena Van Damme, Guillaume E. Courtoy, Romina Mora Barthelmess, Jolien Van Craenenbroeck, Els Lebegge, Yvon Elkrim, Naela Assaf, Yves Heremans, et al.
Similarity between mouse/human tiTregs and the activation state of tiTreg subsets in E0771 model
Website
Google Scholar
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S9 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
by Sana M. Arnouk, Daliya Kancheva, Helena Van Damme, Guillaume E. Courtoy, Romina Mora Barthelmess, Jolien Van Craenenbroeck, Els Lebegge, Yvon Elkrim, Naela Assaf, Yves Heremans, et al.
Similarity between mouse/human tiTregs and the activation state of tiTreg subsets in E0771 model
Open Access
Website
Google Scholar
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S11 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
by Sana M. Arnouk, Daliya Kancheva, Helena Van Damme, Guillaume E. Courtoy, Romina Mora Barthelmess, Jolien Van Craenenbroeck, Els Lebegge, Yvon Elkrim, Naela Assaf, Yves Heremans, et al.
IL1R2 is functionally redundant on tiTregs
Website
Google Scholar
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S11 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
by Sana M. Arnouk, Daliya Kancheva, Helena Van Damme, Guillaume E. Courtoy, Romina Mora Barthelmess, Jolien Van Craenenbroeck, Els Lebegge, Yvon Elkrim, Naela Assaf, Yves Heremans, et al.
IL1R2 is functionally redundant on tiTregs
Open Access
Website
Google Scholar
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
by Sana M. Arnouk, Daliya Kancheva, Helena Van Damme, Guillaume E. Courtoy, Romina Mora Barthelmess, Jolien Van Craenenbroeck, Els Lebegge, Yvon Elkrim, Naela Assaf, Yves Heremans, et al.
Transcriptomic analysis of the different cell populations infiltrating human TNBC and CRC tumors
Website
Google Scholar
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S4 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
by Sana M. Arnouk, Daliya Kancheva, Helena Van Damme, Guillaume E. Courtoy, Romina Mora Barthelmess, Jolien Van Craenenbroeck, Els Lebegge, Yvon Elkrim, Naela Assaf, Yves Heremans, et al.
Transcriptomic analysis of the different cell populations infiltrating human TNBC and CRC tumors
Open Access
Website
Google Scholar
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
by Sana M. Arnouk, Daliya Kancheva, Helena Van Damme, Guillaume E. Courtoy, Romina Mora Barthelmess, Jolien Van Craenenbroeck, Els Lebegge, Yvon Elkrim, Naela Assaf, Yves Heremans, et al.
TiTreg subsets in the MC38 model
Website
Google Scholar
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S6 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
by Sana M. Arnouk, Daliya Kancheva, Helena Van Damme, Guillaume E. Courtoy, Romina Mora Barthelmess, Jolien Van Craenenbroeck, Els Lebegge, Yvon Elkrim, Naela Assaf, Yves Heremans, et al.
TiTreg subsets in the MC38 model
Open Access
Website
Google Scholar
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S10 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
by Sana M. Arnouk, Daliya Kancheva, Helena Van Damme, Guillaume E. Courtoy, Romina Mora Barthelmess, Jolien Van Craenenbroeck, Els Lebegge, Yvon Elkrim, Naela Assaf, Yves Heremans, et al.
Prediction of the active regulons in the different tiTreg clusters as determined via SCENIC
Website
Google Scholar
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S10 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
by Sana M. Arnouk, Daliya Kancheva, Helena Van Damme, Guillaume E. Courtoy, Romina Mora Barthelmess, Jolien Van Craenenbroeck, Els Lebegge, Yvon Elkrim, Naela Assaf, Yves Heremans, et al.
Prediction of the active regulons in the different tiTreg clusters as determined via SCENIC
Open Access
Website
Google Scholar
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S14 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
by Sana M. Arnouk, Daliya Kancheva, Helena Van Damme, Guillaume E. Courtoy, Romina Mora Barthelmess, Jolien Van Craenenbroeck, Els Lebegge, Yvon Elkrim, Naela Assaf, Yves Heremans, et al.
Some TME immune components of E0771 and MC38 tumors when treated with anti-IL1R2 Nb-Fc monotherapy
Website
Google Scholar
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S14 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
by Sana M. Arnouk, Daliya Kancheva, Helena Van Damme, Guillaume E. Courtoy, Romina Mora Barthelmess, Jolien Van Craenenbroeck, Els Lebegge, Yvon Elkrim, Naela Assaf, Yves Heremans, et al.
Some TME immune components of E0771 and MC38 tumors when treated with anti-IL1R2 Nb-Fc monotherapy
Open Access
Website
Google Scholar
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
by Sana M. Arnouk, Daliya Kancheva, Helena Van Damme, Guillaume E. Courtoy, Romina Mora Barthelmess, Jolien Van Craenenbroeck, Els Lebegge, Yvon Elkrim, Naela Assaf, Yves Heremans, et al.
Representative gating strategy for the different lymphoid and myeloid cell subsets infiltrating the TME
Website
Google Scholar
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S1 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
by Sana M. Arnouk, Daliya Kancheva, Helena Van Damme, Guillaume E. Courtoy, Romina Mora Barthelmess, Jolien Van Craenenbroeck, Els Lebegge, Yvon Elkrim, Naela Assaf, Yves Heremans, et al.
Representative gating strategy for the different lymphoid and myeloid cell subsets infiltrating the TME
Open Access
Website
Google Scholar
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
by Sana M. Arnouk, Daliya Kancheva, Helena Van Damme, Guillaume E. Courtoy, Romina Mora Barthelmess, Jolien Van Craenenbroeck, Els Lebegge, Yvon Elkrim, Naela Assaf, Yves Heremans, et al.
TiTreg subsets in the E0771 model
Website
Google Scholar
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S5 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
by Sana M. Arnouk, Daliya Kancheva, Helena Van Damme, Guillaume E. Courtoy, Romina Mora Barthelmess, Jolien Van Craenenbroeck, Els Lebegge, Yvon Elkrim, Naela Assaf, Yves Heremans, et al.
TiTreg subsets in the E0771 model
Open Access
Website
Google Scholar
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S13 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
by Sana M. Arnouk, Daliya Kancheva, Helena Van Damme, Guillaume E. Courtoy, Romina Mora Barthelmess, Jolien Van Craenenbroeck, Els Lebegge, Yvon Elkrim, Naela Assaf, Yves Heremans, et al.
Results of the monotherapy with different anti-IL1R2 Nb-Fc constructs in E0771 and MC38 tumor-bearing mice
Website
Google Scholar
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S13 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
by Sana M. Arnouk, Daliya Kancheva, Helena Van Damme, Guillaume E. Courtoy, Romina Mora Barthelmess, Jolien Van Craenenbroeck, Els Lebegge, Yvon Elkrim, Naela Assaf, Yves Heremans, et al.
Results of the monotherapy with different anti-IL1R2 Nb-Fc constructs in E0771 and MC38 tumor-bearing mice

Show all